The inspection was carried out from July 8 to 12 July 2019
Laurus Labs, a leading research and development-driven and fully-integrated pharmaceutical company in India, announced that the maiden US FDA audit for its Unit 4 was successfully completed without any observations and no form 483 issued. The inspection was carried out from July 8 to 12 July 2019.
- Advertisement -